Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held this year in the vibrant city ...

The phase I clinical trial included ten patients with relapsed or refractory classical Hodgkin lymphoma or CD30-positive T-cell lymphoma, with very positive results. According to Dr. Javier Briones, ...

The Phase I trial involved 10 patients with relapsed or refractory classical Hodgkin lymphoma or CD30 + T-cell lymphoma, yielding highly positive results. Dr. Javier Briones, Head of the ...

Promising results in the Phase I clinical trial The Phase I clinical trial involved ten patients with relapsed or refractory classical Hodgkin lymphoma or CD30+ T-cell lymphoma, yielding highly ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Promising Results in the Phase I Clinical Trial The phase I clinical trial included ten patients with relapsed or refractory classical Hodgkin lymphoma or CD30-positive T-cell lymphoma ...

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. I ...

In October, a typically determined Joe Thompson took part in a 21-mile fundraising walk to raise cancer awareness. He was ...